As of 2026, at least six registered human clinical trials are evaluating fisetin for aging-related outcomes. The most advanced, the PEARL trial (NCT02555878), evaluated fisetin 20 mg/kg/day × 2 days in older adults with adiposity and has reported preliminary positive findings on circulating senescence biomarkers. No significant adverse events have been reported across trials.

Are the fisetin trial results published?

Some preliminary data has been presented at aging research conferences (ICAD, AGS Annual Meeting) and included in grant renewal applications. Full peer-reviewed publications from PEARL are anticipated in 2025–2026.

Can I participate in a fisetin clinical trial?

Check ClinicalTrials.gov for open enrollment. Search "fisetin senolytic" or "fisetin aging." Many trials seek participants aged 65+ with specific health characteristics.